Short Term Rating on Quintiles Transitional Holdings (Q)

Quintiles Transitional Holdings (Q) : Zacks Investment Research ranks Quintiles Transitional Holdings (Q) as 3, which is a Hold recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 1.65, which indicates as a Buy.

Quintiles Transitional Holdings (Q) : The most positive equity analysts on Quintiles Transitional Holdings (Q) expects the shares to touch $83, whereas, the least positive believes that the stock will trade at $62 in the short term. The company is covered by 10 Wall Street Brokerage Firms. The average price target for shares are $74.75 with an expected fluctuation of $6.21 from the mean.

For the current week, the company shares have a recommendation consensus of Buy.


Quintiles Transitional Holdings (NYSE:Q): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $71.42 and $70.93 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $71.71. The buying momentum continued till the end and the stock did not give up its gains. It closed at $71.06, notching a gain of 0.34% for the day. The total traded volume was 1,760,360 . The stock had closed at $70.82 on the previous day.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *